CA2978537C - Utilisations therapeutiques de l'ibogaine et composes associes - Google Patents

Utilisations therapeutiques de l'ibogaine et composes associes Download PDF

Info

Publication number
CA2978537C
CA2978537C CA2978537A CA2978537A CA2978537C CA 2978537 C CA2978537 C CA 2978537C CA 2978537 A CA2978537 A CA 2978537A CA 2978537 A CA2978537 A CA 2978537A CA 2978537 C CA2978537 C CA 2978537C
Authority
CA
Canada
Prior art keywords
ibogaine
dosage
patient
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2978537A
Other languages
English (en)
Other versions
CA2978537A1 (fr
Inventor
Emeline Maillet
Lawrence Friedhoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DemeRx Inc
Original Assignee
DemeRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DemeRx Inc filed Critical DemeRx Inc
Priority to CA3212001A priority Critical patent/CA3212001A1/fr
Publication of CA2978537A1 publication Critical patent/CA2978537A1/fr
Application granted granted Critical
Publication of CA2978537C publication Critical patent/CA2978537C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Abstract

D'une manière générale, la présente invention concerne des procédés et des compositions associés à des utilisations thérapeutiques de l'ibogaïne, d'un dérivé de l'ibogaïne, ou un sel et/ou un solvate pharmaceutiquement acceptable de celui-ci.
CA2978537A 2014-03-03 2015-03-02 Utilisations therapeutiques de l'ibogaine et composes associes Active CA2978537C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3212001A CA3212001A1 (fr) 2014-03-03 2015-03-02 Utilisations therapeutiques de l'ibogaine et composes associes

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201461947397P 2014-03-03 2014-03-03
US61/947,397 2014-03-03
US201461952718P 2014-03-13 2014-03-13
US201461952724P 2014-03-13 2014-03-13
US201461952743P 2014-03-13 2014-03-13
US201461952736P 2014-03-13 2014-03-13
US201461952740P 2014-03-13 2014-03-13
US201461952725P 2014-03-13 2014-03-13
US61/952,740 2014-03-13
US61/952,718 2014-03-13
US61/952,724 2014-03-13
US61/952,736 2014-03-13
US61/952,743 2014-03-13
US61/952,725 2014-03-13
US201462049968P 2014-09-12 2014-09-12
US62/049,968 2014-09-12
PCT/US2015/018356 WO2015134405A1 (fr) 2014-03-03 2015-03-02 Utilisations therapeutiques de l'ibogaïne et composes associes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3212001A Division CA3212001A1 (fr) 2014-03-03 2015-03-02 Utilisations therapeutiques de l'ibogaine et composes associes

Publications (2)

Publication Number Publication Date
CA2978537A1 CA2978537A1 (fr) 2015-09-11
CA2978537C true CA2978537C (fr) 2023-10-24

Family

ID=54055765

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2978537A Active CA2978537C (fr) 2014-03-03 2015-03-02 Utilisations therapeutiques de l'ibogaine et composes associes
CA3212001A Pending CA3212001A1 (fr) 2014-03-03 2015-03-02 Utilisations therapeutiques de l'ibogaine et composes associes

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3212001A Pending CA3212001A1 (fr) 2014-03-03 2015-03-02 Utilisations therapeutiques de l'ibogaine et composes associes

Country Status (4)

Country Link
EP (1) EP3113771A4 (fr)
AU (2) AU2015225442A1 (fr)
CA (2) CA2978537C (fr)
WO (1) WO2015134405A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9561233B2 (en) 2014-03-13 2017-02-07 Demerx, Inc. Use of ibogaine for the treatment of pain
US9592239B2 (en) 2014-09-12 2017-03-14 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020212948A1 (fr) 2019-04-17 2020-10-22 Compass Pathfinder Limited Procédés pour traiter les troubles neurocognitifs, la douleur chronique, et pour réduire l'inflammation
US11596638B2 (en) * 2019-10-01 2023-03-07 Mind Medicine, Inc 18-MC for treatment of substance use disorders
CN115916215A (zh) * 2020-04-16 2023-04-04 长矛治疗股份有限公司 迷幻剂衍生物的经皮微剂量递送
WO2023278108A1 (fr) * 2021-06-29 2023-01-05 Mind Medicine, Inc. 18-mc pour le traitement de l'obésité

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857523A (en) * 1988-07-18 1989-08-15 Nda International, Inc. Rapid method for attenuating the alcohol dependency syndrome
US5629307A (en) * 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
CA2664935A1 (fr) * 2006-09-26 2008-04-03 Addiction Research Institute, Inc. Compositions de traitement de l'hepatite c et procedes d'utilisation des compositions de traitement de l'hepatite c

Also Published As

Publication number Publication date
EP3113771A1 (fr) 2017-01-11
CA2978537A1 (fr) 2015-09-11
EP3113771A4 (fr) 2017-10-25
AU2020273281B2 (en) 2024-05-02
WO2015134405A1 (fr) 2015-09-11
AU2020273281A1 (en) 2020-12-17
CA3212001A1 (fr) 2015-09-11
AU2015225442A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
CA2978537C (fr) Utilisations therapeutiques de l'ibogaine et composes associes
US10653700B2 (en) Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
AU2020267217B2 (en) Therapeutic methods employing noribogaine and related compounds
US20220023310A1 (en) Methods for acute and long-term treatment of opioid and opioid-like drug addiction
US11077118B2 (en) Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
AU2002342533B2 (en) Prevention of addiction in pain management
CA2994150A1 (fr) Compositions et procedes antitussifs
WO2021063387A1 (fr) Utilisation d'une composition d'imatinib et d'un dérivé de celui-ci dans la préparation d'un médicament pour la prévention, le traitement et le contrôle d'une rechute d'addiction
CA3024081A1 (fr) Procedes de traitement de la dependance aux opioides et des symptomes de sevrage en utilisant de la noribogaine
JP2021530557A (ja) トラジピタントを用いる処置方法
In Materials preparation to the practical classes for the students of pharmaceutical faculty LESSON № 21 Theme 29. Condensed heterocyclic systems. Purine. Notion about alkaloids.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200225

EEER Examination request

Effective date: 20200225

EEER Examination request

Effective date: 20200225

EEER Examination request

Effective date: 20200225

EEER Examination request

Effective date: 20200225

EEER Examination request

Effective date: 20200225

EEER Examination request

Effective date: 20200225

EEER Examination request

Effective date: 20200225

EEER Examination request

Effective date: 20200225